1
|
Frasson-Uemura IG, Biazi GR, Miksza DR, Moreira CCL, Cassolla P, Bertolini GL, Bazotte RB, de Souza HM. Infusion of high concentration of lactate in perfused liver, simulating in vivo hyperlactatemia, prevents the reduction of gluconeogenesis in Walker-256 tumor-bearing rats. J Cell Biochem 2019; 120:11068-11080. [PMID: 30719751 DOI: 10.1002/jcb.28384] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Accepted: 01/10/2019] [Indexed: 01/24/2023]
Abstract
Gluconeogenesis (GN) is increased in patients with cancer cachexia, but is reduced in liver perfusion of Walker-256 tumor-bearing cachectic rats (TB rats). The causes of these differences are unknown. We investigated the influence of circulating concentrations of lactate (NADH generator) and NADH on GN in perfused livers of TB rats. Lactate, at concentrations similar to those found on days 5 (3.0 mM), 8 (5.5 mM), and 12 (8.0 mM) of the tumor, prevented the reduction of GN from 2.0 mM lactate (lactatemia of healthy rat) in TB rats. NADH, 50 or 75 μM, but not 25 μM, increased GN from 2.0 mM lactate in TB rats to higher values than healthy rats. High concentrations of pyruvate (no NADH generator, 5.0 and 8.0 mM) did not prevent the reduction of GN from 2.0 mM pyruvate in TB rats. However, 50 or 75 μM NADH, but not 25 μM, increased GN from 2.0 mM pyruvate in TB rats to similar or higher values than healthy rats. High concentration of glutamine (NADH generator, 2.5 mM) or 50 μM NADH prevented the reduction of GN from 1 mM glutamine in TB rats. Intraperitoneal administration of pyruvate (1.0 mg/kg) or glutamine (0.5 mg/kg) similarly increased the glycemia of healthy and TB rats. In conclusion, high lactate concentration, similar to hyperlactatemia, prevented the reduction of GN in perfused livers of TB rats, an effect probably caused by the increased redox potential (NADH/NAD+ ). Thus, the decreased GN in livers from TB rats is due, at least in part, to the absence of simulation of in vivo hyperlactatemia in liver perfusion studies.
Collapse
Affiliation(s)
| | - Giuliana Regina Biazi
- Department of Physiological Sciences, State University of Londrina, Londrina, Paraná, Brazil
| | - Daniele Romani Miksza
- Department of Physiological Sciences, State University of Londrina, Londrina, Paraná, Brazil
| | | | - Priscila Cassolla
- Department of Physiological Sciences, State University of Londrina, Londrina, Paraná, Brazil
| | - Gisele Lopes Bertolini
- Department of Physiological Sciences, State University of Londrina, Londrina, Paraná, Brazil
| | - Roberto Barbosa Bazotte
- Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, Paraná, Brazil
| | - Helenir Medri de Souza
- Department of Physiological Sciences, State University of Londrina, Londrina, Paraná, Brazil
| |
Collapse
|
2
|
Biazi GR, Frasson IG, Miksza DR, de Morais H, de Fatima Silva F, Bertolini GL, de Souza HM. Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats. J Cell Biochem 2018; 119:7300-7309. [PMID: 29761924 DOI: 10.1002/jcb.27027] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 04/06/2018] [Indexed: 12/17/2022]
Abstract
The response to glucagon and adrenaline in cancer cachexia is poorly known. The aim of this study was to investigate the response to glucagon, adrenergic agonists (α and β) and cyclic adenosine monophosphate (cAMP) on glycogenolysis, gluconeogenesis, and glycolysis in liver perfusion of Walker-256 tumor-bearing rats with advanced cachexia. Liver ATP content was also investigated. Rats without tumor (healthy) were used as controls. Agonists α (phenylephrine) and β (isoproterenol) adrenergic, instead of adrenaline, and cAMP, the second messenger of glucagon and isoproterenol, were used in an attempt to identify mechanisms involved in the responses. Glucagon (1 nM) stimulated glycogenolysis and gluconeogenesis and inhibited glycolysis in the liver of healthy and tumor-bearing rats, but their effects were lower in tumor-bearing rats. Isoproterenol (20 µM) stimulated glycogenolysis, gluconeogenesis, and glycolysis in healthy rats and had virtually no effect in tumor-bearing rats. cAMP (9 µM) also stimulated glycogenolysis and gluconeogenesis and inhibited glycolysis in healthy rats but had practically no effect in tumor-bearing rats. Phenylephrine (2 µM) stimulated glycogenolysis and gluconeogenesis and inhibited glycolysis and these effects were also lower in tumor-bearing rats than in healthy. Liver ATP content was lower in tumor-bearing rats. In conclusion, tumor-bearing rats with advanced cachexia showed a decreased hepatic response to glucagon, adrenergic agonists (α and β), and cAMP in glycogenolysis, gluconeogenesis, and glycolysis, which may be due to a reduced rate of regulatory enzyme phosphorylation caused by the low ATP levels in the liver.
Collapse
Affiliation(s)
- Giuliana R Biazi
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| | - Isabele G Frasson
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| | - Daniele R Miksza
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| | - Hely de Morais
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| | | | - Gisele L Bertolini
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| | - Helenir M de Souza
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, Brazil
| |
Collapse
|
3
|
de Fatima Silva F, Ortiz-Silva M, Galia WBDS, Cassolla P, da Silva FG, Graciano MFR, Carpinelli AR, de Souza HM. Effects of metformin on insulin resistance and metabolic disorders in tumor-bearing rats with advanced cachexia. Can J Physiol Pharmacol 2018; 96:498-505. [DOI: 10.1139/cjpp-2017-0171] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Metformin (MET) is widely used in the correction of insulin (INS) resistance and metabolic abnormalities in type 2 diabetes. However, its effect on INS resistance and metabolic disorders associated with cancer cachexia is not established. We investigated the MET effects, isolated or associated with INS, on INS resistance and metabolic changes induced by Walker-256 tumor in rats with advanced cachexia. MET (500 mg·kg−1, oral) and MET + INS (1.0 IU·kg−1, s.c.) were administered for 12 days, starting on the day of tumor cell inoculation. Tumor-bearing rats showed adipose and muscle mass wasting, body mass loss, anorexia, decreased Akt phosphorylation in retroperitoneal and mesenteric adipose tissue, peripheral INS resistance, hypoinsulinemia, reduced INS content and secretion from pancreatic islets, and also inhibition of glycolysis, gluconeogenesis, and glycogenolysis in liver. MET and MET + INS treatments did not prevent these changes. It can be concluded that treatments with MET and MET + INS did not prevent the adipose and muscle mass wasting and body mass loss of tumor-bearing rats possibly by not improving INS resistance. Therefore, MET, used for the treatment of INS resistance in type 2 diabetes, is not effective in improving INS resistance in the advanced stage of cancer cachexia, evidencing that the drug does not have the same beneficial effect in these 2 diseases.
Collapse
Affiliation(s)
- Flaviane de Fatima Silva
- Department of Physiological Sciences, State University of Londrina, 86051-990, Londrina, PR, Brazil
| | - Milene Ortiz-Silva
- Department of Physiological Sciences, State University of Londrina, 86051-990, Londrina, PR, Brazil
| | | | - Priscila Cassolla
- Department of Physiological Sciences, State University of Londrina, 86051-990, Londrina, PR, Brazil
| | | | | | - Angelo Rafael Carpinelli
- Department of Physiology and Biophysics, University of São Paulo, 05508-900, São Paulo, SP, Brazil
| | - Helenir Medri de Souza
- Department of Physiological Sciences, State University of Londrina, 86051-990, Londrina, PR, Brazil
| |
Collapse
|
4
|
Li N, Chen B, Lin R, Liu N, Dai HT, Tang KY, Yang JY, Huang YH. The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats. Cancer Chemother Pharmacol 2018; 81:207-216. [PMID: 29196964 PMCID: PMC5754402 DOI: 10.1007/s00280-017-3493-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Accepted: 11/27/2017] [Indexed: 02/05/2023]
Abstract
PURPOSE To investigate the optimal starting time point of sorafenib therapy in suppressing the tumor-promoting effects of VEGF up-regulation, which is frequently found after local therapy in clinical practice. METHODS VEGF was intravenously injected to imitate the evaluated expression after local tumor therapy, such as TACE. A total of 40 SD rats bearing hepatic tumors were randomly divided into four groups and sorafenib was administered at different timepoints: (A) control group: VEGF injection only; (B) initiating sorafenib 72 h prior to VEGF injection; (C) initiating sorafenib simultaneously with VEGF injection; (D) initiating sorafenib 72 h post-VEGF injection. The rate of tumor growth, median survival time, expression of VEGF, and microvessel density (MVD), as determined by immunohistochemical (IHC) examination, were compared. RESULTS The results revealed that the tumor size and median survival time were significantly different between the three sorafenib groups compared to the control group (p < 0.05). Median survival times were 19.6 ± 1.78, 31.2 ± 6.99, 27.4 ± 4.9, and 26.5 ± 4.6 days in group A, B, C, and D, respectively. Furthermore, there was a difference in statistical significance between the two sorafenib groups B and D (p = 0.04). Tumors were collected for HE staining and IHC examination. The expression levels of VEGF in B, C, and D were 42.8 ± 7.96, 71.9 ± 15.73, and 73.6 ± 13.73, and all of them were significantly lower than that in the control group (88.3 ± 13.61). Furthermore, the level of MVD was 109.2 ± 8.98 in the control group, which was significantly higher than in the three sorafenib groups (45.7 ± 16.92, 77.1 ± 16.29, and 93.6 ± 12.87, all p < 0.05). CONCLUSIONS According to our results, the most suitable regimen for the administration of sorafenib is before the increased expression of VEGF, which showed a potential advantage for controlling the tumor growth and prolonging the survival time of test animal via inhibiting VEGF-receptor expression through the bifunction of VEGF, and the reduction of tumor angiogenesis.
Collapse
Affiliation(s)
- Nan Li
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Bin Chen
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Run Lin
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Ni Liu
- The Central Hospital of Wuhan, Wuhan, People's Republic of China
| | - Hai-Tao Dai
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Ke-Yu Tang
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Jian-Yong Yang
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China
| | - Yong-Hui Huang
- Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou, 510080, People's Republic of China.
| |
Collapse
|
5
|
Stipp MC, Bezerra IDL, Corso CR, Dos Reis Livero FA, Lomba LA, Caillot ARC, Zampronio AR, Queiroz-Telles JE, Klassen G, Ramos EAS, Sassaki GL, Acco A. Necroptosis mediates the antineoplastic effects of the soluble fraction of polysaccharide from red wine in Walker-256 tumor-bearing rats. Carbohydr Polym 2017; 160:123-133. [PMID: 28115086 DOI: 10.1016/j.carbpol.2016.12.047] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 12/07/2016] [Accepted: 12/18/2016] [Indexed: 12/29/2022]
Abstract
Polysaccharides are substances that modify the biological response to several stressors. The present study investigated the antitumor activity of the soluble fraction of polysaccharides (SFP), extracted from cabernet franc red wine, in Walker-256 tumor-bearing rats. The monosaccharide composition had a complex mixture, suggesting the presence of arabinoglactans, mannans, and pectins. Treatment with SFP (30 and 60mg/kg, oral) for 14days significantly reduced the tumor weight and volume compared with controls. Treatment with 60mg/kg SFP reduced blood monocytes and neutrophils, reduced the tumor activity of N-acetylglucosaminidase, myeloperoxidase, and nitric oxide, increased blood lymphocytes, and increased the levels of tumor necrosis factor α (TNF-α) in tumor tissue. Treatment with SFP also induced the expression of the cell necroptosis-related genes Rip1 and Rip3. The antineoplastic effect of SFP appears to be attributable to its action on the immune system by controlling the tumor microenvironment and stimulating TNF-α production, which may trigger the necroptosis pathway.
Collapse
Affiliation(s)
| | | | - Claudia Rita Corso
- Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil
| | | | | | | | | | | | - Giseli Klassen
- Department of Basic Pathology, Federal University of Paraná, Curitiba, PR, Brazil
| | - Edneia A S Ramos
- Department of Basic Pathology, Federal University of Paraná, Curitiba, PR, Brazil
| | - Guilherme Lanzi Sassaki
- Department of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba, PR, Brazil
| | - Alexandra Acco
- Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
| |
Collapse
|
6
|
de Souza CO, Kurauti MA, de Fatima Silva F, de Morais H, Borba-Murad GR, de Andrade FG, de Souza HM. Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats. Mol Cell Biochem 2014; 399:237-46. [PMID: 25359170 DOI: 10.1007/s11010-014-2250-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 10/17/2014] [Indexed: 12/22/2022]
Abstract
The contribution of anti-inflammatory property of celecoxib in the improvement of metabolic disorders in cancer is unknown. The purpose of this study was to compare the effects of celecoxib and ibuprofen, non-steroidal anti-inflammatory drugs (NSAIDs), on several metabolic changes observed in Walker-256 tumor-bearing rats. The effects of these NSAIDs on the tumor growth were also assessed. Celecoxib or ibuprofen (both at 25 mg/Kg) was administered orally for 12 days, beginning on the day the rats were inoculated with Walker-256 tumor cells. Celecoxib treatment prevented the losses in body mass and mass of retroperitoneal adipose tissue, gastrocnemius, and extensor digitorum longus muscles in tumor-bearing rats. Celecoxib also prevented the rise in blood levels of triacylglycerol, urea, and lactate, the inhibition of peripheral response to insulin and hepatic glycolysis, and tended to attenuate the decrease in the food intake, but had no effect on the reduction of glycemia induced by the tumor. In addition, celecoxib treatment increased the number of Walker-256 cells with signs of apoptosis and the tumor necrosis area and prevented the tumor growth. In contrast, ibuprofen treatment had no effect on metabolic parameters affected by the Walker-256 tumor or tumor growth. It can be concluded that celecoxib, unlike ibuprofen, ameliorated several metabolic changes in rats with Walker-256 tumor due to its anti-tumor effect and not its anti-inflammatory property.
Collapse
Affiliation(s)
- Camila Oliveira de Souza
- Department of Physiological Sciences, State University of Londrina, Londrina, PR, 86051-990, Brazil
| | | | | | | | | | | | | |
Collapse
|
7
|
Vascular endothelial growth factor accelerates establishment of a model of hepatic metastasis in Walker-256 tumor-bearing rats. Am J Med Sci 2014; 349:234-9. [PMID: 25310512 DOI: 10.1097/maj.0000000000000359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
BACKGROUND Animal models of secondary liver cancer are limited by the time required for the development of hepatic metastases. The authors administered vascular endothelial growth factor (VEGF) to stimulate tumor growth in a model of hepatic metastasis. METHODS A 0.5 to 1.0 mm³ Walker-256 carcinosarcoma tumor tissue was implanted into the livers of 45 Sprague-Dawley rats, randomly assigned to 3 equal groups to receive daily injections (0.1 mL), for 1 week, of either normal saline (control group), 20 mg/L VEGF (VEGF-20 group) or 40 mg/L VEGF (VEGF-40 group). Tumor growth was assessed by magnetic resonance imaging after 3, 7 and 14 days, and overall survival was recorded. RESULTS Three days after implantation, no tumors were detected by magnetic resonance imaging in the control group. In contrast, tumors were observed in 50% of rats in the VEGF-20 group and 66.7% of rats in the VEGF-40 group (P < 0.05). By day 7, tumors were detected in 92.8% of rats in the VEGF-20 group, 86.7% of rats in the VEGF-40 group, but only 21.4% of rats in the control group (P < 0.05). Tumor size increased progressively, reaching 1.81 ± 0.08, 2.51 ± 0.12 and 2.67 ± 0.10 cm³ in the control, VEGF-20 and VEGF-40 groups, respectively, 14 days after implantation of tumor tissue. Median survival times were significantly shorter in the VEGF-40 group (15 days) than in the control and VEGF-20 groups (27 and 25, respectively) (both P < 0.05). CONCLUSIONS Daily VEGF injection (20 mg/L, 1 week) accelerates tumorigenesis without compromising survival, potentially extending the period in which experiments can be conducted in this model.
Collapse
|
8
|
Decreased response to cAMP in the glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats. Mol Cell Biochem 2012; 368:9-16. [PMID: 22638647 DOI: 10.1007/s11010-012-1337-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2011] [Accepted: 05/03/2012] [Indexed: 01/11/2023]
Abstract
The hepatic response to cyclic adenosine monophosphate (cAMP) and N6-monobutyryl-cAMP (N6-MB-cAMP) in the glucose and glycogen catabolism and hepatic glycogen levels were evaluated in Walker-256 tumor-bearing rats, on days 5 (WK5), 8 (WK8), and 11 (WK11) after the implantation of tumor. Rats without tumor fed ad libitum (fed control rats) or that received the same daily amount of food ingested by anorexics tumor-bearing rats (pair-fed control rats) or 24 h fasted (fasted control rats) were used as controls. Glucose and glycogen catabolism were measured in perfused liver. Hepatic glycogen levels were lower (p < 0.05) in WK5, WK8, and WK11 rats in comparison with fed control rats, but not in relation to the pair-fed control rats. However, the stimulatory effect of cAMP (3 and 9 μM) in the glycogen catabolism was lower (p < 0.05), respectively, in WK5 and WK8 rats compared to the pair-fed and fed control rats. Accordingly, the suppressive effect of cAMP (6 μM) in the glucose catabolism, under condition of depletion of hepatic glycogen (24 h fast), was lower (p < 0.05) in WK5 and WK11 rats than in fasted control rats. Similarly, the suppressive effect of N6-MB-cAMP (1 μM), a synthetic analogue of cAMP that it is not degraded by phosphodiesterase 3B (PDE3B), in the glucose catabolism was lower (p < 0.05) in WK5 rats compared to fasted control rats. In conclusion, livers of Walker-256 tumor-bearing rats showed lower response to cAMP in the glucose and glycogen catabolism in various stages of tumor development (days 5, 8 and 11), which was probably not due to the lower hepatic glycogen levels nor due to the increased activity of PDE3B.
Collapse
|
9
|
Dreifuss AA, Bastos-Pereira AL, Avila TV, Soley BDS, Rivero AJ, Aguilar JL, Acco A. Antitumoral and antioxidant effects of a hydroalcoholic extract of cat's claw (Uncaria tomentosa) (Willd. Ex Roem. & Schult) in an in vivo carcinosarcoma model. JOURNAL OF ETHNOPHARMACOLOGY 2010; 130:127-133. [PMID: 20435132 DOI: 10.1016/j.jep.2010.04.029] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2010] [Revised: 04/05/2010] [Accepted: 04/20/2010] [Indexed: 05/29/2023]
Abstract
AIM OF THE STUDY The present work intended to study the antitumoral and antioxidant effects of Uncaria tomentosa (UT) hydroalcoholic extract in the Walker-256 cancer model. METHODS AND MATERIALS Walker-256 cells were subcutaneously inoculated in the pelvic limb of male Wistar rats. Daily gavage with UT extract (10, 50 or 100 mg kg(-1), Groups UT) or saline solution (Control, Group C) was subsequently initiated, until 14 days afterwards. For some parameters, a group of healthy rats (Baseline, Group B) was added. At the end of treatment the following parameters were evaluated: (a) tumor volume and mass; (b) plasmatic concentration of urea, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) and lactate dehydrogenase (LDH); (c) hepatic and tumoral activity of catalase (CAT) and superoxide dismutase (SOD), as well as the rate of lipid peroxidation (LPO) and gluthatione (GSH); and (d) hepatic glutathione-S-transferase (GST) activity. The reactivity of UT extract with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) was assessed in parallel. RESULTS UT hydroalcoholic extract successfully reduced the tumor growth. In addition, treatment with UT reduced the activity of AST, which had been increased as a result of tumor inoculation, thus attempting to return it to normal levels. UT did not reverse the increase of LDH and GGT plasma levels, although all doses were remarkably effective in reducing urea plasma levels. An important in vitro free radical-scavenging activity was detected at various concentrations of UT extract (1-300 microg mL(-1)). Treatment also resulted in increased CAT activity in liver, while decreasing it in tumor tissue. SOD activity was reduced in liver as well as in tumor, compared to Group C. No statistical significance concerning ALT, GST, LPO or GSH were observed. CONCLUSIONS This data represent an in vivo demonstration of both antitumoral and antioxidant effects of UT hydroalcoholic extract. The antineoplastic activity may result, partially at least, from the ability of UT to regulate redox and metabolism homeostasis.
Collapse
|
10
|
Jumes FMD, Lugarini D, Pereira ALB, de Oliveira A, Christoff ADO, Linde GA, do Valle JS, Colauto NB, Acco A. Effects of Agaricus brasiliensis mushroom in Walker-256 tumor-bearing rats. Can J Physiol Pharmacol 2010; 88:21-7. [DOI: 10.1139/y09-111] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Agaricus brasiliensis is a mushroom native to São Paulo State, Brazil, that is studied for its medicinal proprieties. This work aimed to investigate the antitumoral activity of A. brasiliensis extracts and pure powdered basidiocarp preparation using Walker-256 (W256) tumor-bearing rats, a model for cancer-related cachexia studies. The rats were treated for 14 days by gavage (136 mg/kg) and at the end of the experiment tumors were collected to calculate mass and volume. Blood was collected for determination of plasma glucose, albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Hepatic and tumor enzymes indicating oxidative stress were also evaluated. The results showed that all 4 treatments (pure powdered basidiocarp and aqueous, acid, and alkaline extracts) significantly reduced tumor size and promoted gain in body weight. Plasmatic analysis showed a reduction in AST level and increased glycemia in the treated rats. Pure basidiocarp preparations improved the liver catalase and superoxide dismutase activity, but did not change the glutathione S-transferase activity. The data collected from the W256 tumor-bearing rats revealed the beneficial effects of A. brasiliensis in tumor treatment, mainly related to cachexia. The benefits can be partly related to antioxidant activity and to reduction of weight loss and tumor growth.
Collapse
Affiliation(s)
- Fernanda Menon Dias Jumes
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Daiana Lugarini
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Amanda Leite Bastos Pereira
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Anabel de Oliveira
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Adriana de Oliveira Christoff
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Giani Andrea Linde
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Juliana Silveira do Valle
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Nelson Barros Colauto
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| | - Alexandra Acco
- Pharmacology Department, Federal University of Paraná, Jardim das Américas, C.P. 19031, 81531-900 Curitiba – PR, Brazil
- Molecular Biology Laboratory, Paranaense University, Praça Mascarenhas de Moraes, 4282, C.P. 224, 87502-210 Umuarama – PR, Brazil
| |
Collapse
|
11
|
de Sá-Nakanishi AB, Bracht F, Yamamoto NS, Padilha F, Kelmer-Bracht AM, Bracht A. The action of extracellular NAD+ in the liver of healthy and tumor-bearing rats: model analysis of the tumor-induced modified response. Exp Mol Pathol 2008; 84:218-25. [PMID: 18387605 DOI: 10.1016/j.yexmp.2008.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2007] [Revised: 01/30/2008] [Accepted: 02/01/2008] [Indexed: 10/22/2022]
Abstract
The chronic inflammatory state induced by cancer is expected to affect the actions of extracellular NAD(+) in the liver because these are largely mediated by eicosanoids. Under this assumption the present work was planned to investigate the influence of the Walker-256 tumor on the action of extracellular NAD(+) on metabolism and hemodynamics in the perfused rat liver. The experiments were done with livers from healthy and tumor-bearing rats with measurements of gluconeogenesis from lactate, pyruvate production, oxygen consumption and portal pressure. A model describing the biphasic effects of NAD(+) was proposed as an auxiliary worktool for interpretation. The Walker-256 tumor modified the responses of metabolism to extracellular NAD(+) by delaying the peak of maximal responses and by prolonging the inhibitory effects. The transient increase in portal perfusion pressure caused by NAD(+) was enhanced and delayed. The model was constructed assuming the mediation of a down-regulator (inhibition), an up-regulator (stimulation) and receptor dessensitization. Analysis suggested that the productions of both the down- and up-regulators were substantially increased and delayed in time in the tumor-bearing condition. Since the regulators are probably eicosanoids, this analysis is consistent with the increased capacity of producing these agents in the chronic inflammatory state induced by cancer.
Collapse
|
12
|
Acco A, Alves da Silva MHDR, Batista MR, Yamamoto NS, Bracht A. Action of Celecoxib on Hepatic Metabolic Changes Induced by the Walker-256 Tumour in Rats. Basic Clin Pharmacol Toxicol 2007; 101:294-300. [PMID: 17910611 DOI: 10.1111/j.1742-7843.2007.00124.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The purpose of the present work was to investigate the influence of celecoxib on some hepatic metabolic parameters affected by the Walker-256 tumour in rats. Celecoxib was administered daily (5-50 mg/kg body weight) beginning at the day in which the tumour cells were inocculated. At day 14, the liver was isolated and perfused in order to measure alanine transformation, glycolysis and arginine transformation. Maximal reduction of tumour growth (75%), accompanied by an almost normal weight gain, was attained with a celecoxib dose of 12.5 mg/kg. Diminution of glucose utilization (glycolysis) and inhibition of gluconeogenesis and ureogenesis from alanine caused by the tumor were totally reversed by celecoxib. Oxygen uptake by the liver was also normalized by the drug. Hepatic arginine transformation, which is normally enhanced in rats bearing the Walker-256 tumour, remained elevated in celecoxib-treated animals. It was concluded that preservation of gluconeogenesis and normalization of hepatic glucose utilization can explain, partly at least, the clinical improvement of cancer patients treated with the drug. The lack of action of celecoxib on arginine hydrolysis might indicate that reduction in polyamine synthesis is not a factor contributing to the diminished tumour growth.
Collapse
Affiliation(s)
- Alexandra Acco
- Department of Pharmacology, Federal University of Paraná, Curitiba, Brazil
| | | | | | | | | |
Collapse
|
13
|
Caperuto EC, Tomatieli RV, Colquhoun A, Seelaender MCL, Costa Rosa LFBP. β-Hydoxy-β-methylbutyrate supplementation affects Walker 256 tumor-bearing rats in a time-dependent manner. Clin Nutr 2007; 26:117-22. [PMID: 17011676 DOI: 10.1016/j.clnu.2006.05.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2005] [Revised: 03/27/2006] [Accepted: 05/24/2006] [Indexed: 11/16/2022]
Abstract
BACKGROUND & AIMS Cancer cachexia affects intermediary metabolism with intense and general catabolism. Walker 256 tumor is a model injected either subcutaneously (Sc) or intraperitoneally (Ip), with different metabolic features. Beta-hydroxy beta-methylbutyrate (HMbeta) is a leucine metabolite with anti-catabolic properties, the aim of this study being to investigate its effects on metabolic parameters in both tumor models. METHODS Controls (subcutaneous control group (ScC) and intraperitoneal control group (IpC)) and supplemented animals (subcutaneous supplemented group (ScS) and intraperitoneal supplemented group (IpS)) showed these results. RESULTS Protein Sc values were (47.8%) lower than Ip groups. Sc group fat content was (65.16%) higher than Ip groups. Liver glycogen value for Sc groups was (38.4%) higher than Ip groups. Muscle glycogen value for Sc groups were (2.75 times) higher than Ip groups. Corticosterone and insulin values were lower (44.53%) and higher (45.94%), respectively, in Sc when compared with Ip groups. Glucose and lactate values for ScS were the lowest (61.7% and 41.53%) compared to other groups. ScC glutamine value was the highest (40.8%) of all groups. Glutamate Sc values were (42.65%) lower than Ip groups. Sc groups showed greater survival time compared with Ip groups. ScS group showed 100% increase in survival time when compared with ScC. CONCLUSIONS HMbeta supplementation can increase survival time and promotes metabolic changes in cancer-bearing animals, but it seems to work in a time-dependent manner.
Collapse
Affiliation(s)
- Erico Chagas Caperuto
- Biomedical Sciences Institute, Cell Biology and Development, Lineu Prestes Av. 1524 ICB 1 Room 430, 05508-900 Sao Paulo, Sao Paulo, Brazil
| | | | | | | | | |
Collapse
|
14
|
da Veiga RP, da Silva MHRA, Teodoro GR, Yamamoto NS, Constantin J, Bracht A. Metabolic fluxes in the liver of rats bearing the Walker-256 tumour: influence of the circulating levels of substrates and fatty acids. Cell Biochem Funct 2007; 26:51-63. [PMID: 17265532 DOI: 10.1002/cbf.1398] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Studies on fatty acid and amino acid metabolism in the liver of Walker-256 tumour-bearing rats have revealed several changes. Comparisons, however, have been based on experiments performed with non-physiological, frequently unrealistic, substrate concentrations. The aim of the present work was to examine the influence of physiological substrate concentrations on gluconeogenesis, ketogenesis and related parameters. Isolated livers were perfused and substrates were infused at concentrations that were reported to occur in healthy and tumour-bearing rats. Ketogenesis and the mitochondrial NADH/NAD+ ratio were smaller in the tumour-bearing condition at low (0.2 mM) and high (0.8 mM) oleate concentrations. In the absence of oleate, gluconeogenesis from alanine (0.7 mM) and gluconeogenesis plus the associated changes in oxygen uptake due to lactate/pyruvate (2/0.2 and 6/0.3 mM) were smaller in livers of tumour-bearing rats. However, the response of gluconeogenesis from lactate/pyruvate in livers of tumour-bearing rats to 0.8 mM oleate was more pronounced so that a trend towards normalization was apparent at high substrate and oleate concentrations. Gluconeogenesis from 0.7 mM alanine was not significantly changed by oleate in the tumour-bearing state; in the control condition, stimulation occurred at 0.2 mM oleate and inhibition at 0.8 mM oleate. This diminution almost equalized the hepatic alanine-dependent gluconeogenesis of both control and tumour-bearing rats. Ureogenesis was smaller in the tumour-bearing state and was not affected by oleate. It was concluded that the high concentrations of fatty acids and lactate/pyruvate, which predominate in rats bearing the Walker-256 tumour, could be effective in normalizing the gluconeogenic response of livers from tumour-bearing rats.
Collapse
Affiliation(s)
- Renata P da Veiga
- Laboratory of Liver Metabolism, Department of Biochemistry, University of Maringá, Maringá, Brazil
| | | | | | | | | | | |
Collapse
|
15
|
Corbello Pereira SR, Darronqui E, Constantin J, da Silva MHDRA, Yamamoto NS, Bracht A. The urea cycle and related pathways in the liver of Walker-256 tumor-bearing rats. Biochim Biophys Acta Mol Basis Dis 2004; 1688:187-96. [PMID: 15062868 DOI: 10.1016/j.bbadis.2003.12.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2003] [Revised: 12/02/2003] [Accepted: 12/03/2003] [Indexed: 11/28/2022]
Abstract
The urea cycle was evaluated in perfused livers isolated from cachectic tumor-bearing rats (Walker-256 tumor). Urea production in livers of tumor-bearing rats was decreased in the presence of the following substrates: alanine, alanine + ornithine, alanine + aspartate, ammonia, ammonia + lactate, ammonia + pyruvate and glutamine. Urea production from arginine was higher in livers of tumor-bearing rats. No difference was found with aspartate, aspartate + ammonia, citrulline, citrulline + aspartate and glutamine + aspartate. Ammonia consumption was smaller in livers from cachectic rats when the substance was infused together with lactate and pyruvate. Glucose production was smaller in the cachectic condition only when alanine was the gluconeogenic substrate. Blood urea was higher in tumor-bearing rats, suggesting higher rates of urea production. The availability of aspartate seems to be critical for urea synthesis in the liver of tumor-bearing rats, which is possibly unable to produce this amino acid in sufficient amounts from endogenous sources. The liver of tumor-bearing rats may have a different exogenous substrate supply of nitrogenous compounds. Arginine could be one of these compounds in addition to aspartate which seems to be essential for an efficient ureogenesis in tumor-bearing rats.
Collapse
|